Studies with a strong clinical focus, such as those seeking prognostic biomarkers in T1DM and risk factors in T2DM, had higher reporting quality than the more technically oriented studies aimed at detecting hypoglycemia from CGM data or noninvasive methods or developing insulin bolus calculator algorithms. The gene discussed is INS; the disease is type 2 diabetes mellitus.